MTOR and prostate carcinoma: According to Sherer et al., the use of older immunosuppressants such as cyclosporine, azathioprine, and tacrolimus may increase the risk of developing prostate cancer compared to the use of newer agents such as the mammalian target of rapamycin (mTOR) inhibitor [31].